These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3167218)

  • 1. 13-cis-retinoic acid v placebo in myelodysplasia.
    Jacobs A; Clark RE
    Blood; 1988 Oct; 72(4):1439-40. PubMed ID: 3167218
    [No Abstract]   [Full Text] [Related]  

  • 2. 13-cis-retinoic acid in myelodysplastic syndromes.
    Greenberg BR; Buzaid AC; Meyskens FL
    J Clin Oncol; 1986 Aug; 4(8):1282. PubMed ID: 3525772
    [No Abstract]   [Full Text] [Related]  

  • 3. Differentiation therapy of myelodysplastic syndromes with retinoic acid.
    Ohno R
    Leuk Lymphoma; 1994 Aug; 14(5-6):401-9. PubMed ID: 7812199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders.
    Koeffler HP; Heitjan D; Mertelsmann R; Kolitz JE; Schulman P; Itri L; Gunter P; Besa E
    Blood; 1988 Mar; 71(3):703-8. PubMed ID: 3278754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome.
    Clark RE; Jacobs A; Lush CJ; Smith SA
    Lancet; 1987 Apr; 1(8536):763-5. PubMed ID: 2882180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of treatment with 13-cis-retinoic acid and ara-C on the hematopoietic stem cells of patients with myelodysplastic syndromes].
    García Marco J; Miguel Sosa A; García Conde J; Miguel García A; Arbona C; Escrig V; Benet I; Navarro I; Ruiz A; Carbonell F
    Sangre (Barc); 1994 Aug; 39(4):241-4. PubMed ID: 7985051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-trans retinoic acid improves erythropoiesis in myelodysplastic syndromes: a case report.
    Visani G; Cenacchi A; Tosi P; Finelli C; Fogli M; Gamberi B; Martinelli G; Tura S
    Br J Haematol; 1992 Jul; 81(3):444-6. PubMed ID: 1390219
    [No Abstract]   [Full Text] [Related]  

  • 8. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid.
    Letendre L; Levitt R; Pierre RV; Schroeder G; Krook JA; Mailliard JE; Morton RF; Tschetter LK
    Am J Hematol; 1995 Apr; 48(4):233-6. PubMed ID: 7717370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 13-cis-Retinoic acid treatment in patients with myelodysplastic syndrome.
    Leoni F; Ciolli S; Longo G; Messori A; Ferrini PR
    Acta Haematol; 1988; 80(1):8-12. PubMed ID: 3135696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG).
    Hellström E; Robèrt KH; Samuelsson J; Lindemalm C; Grimfors G; Kimby E; Oberg G; Winqvist I; Billström R; Carneskog J
    Eur J Haematol; 1990 Nov; 45(5):255-61. PubMed ID: 2261951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [All-trans-retinoic acid in the differential therapy of proliferative hemocytic diseases. I. Properties of biological retinoids].
    Skotnicki AB; Sledziowski P; Sacha T; Jurczak W
    Przegl Lek; 1995; 52(1):31-4. PubMed ID: 7784610
    [No Abstract]   [Full Text] [Related]  

  • 12. Retinoic acid in mono- or combined differentiation therapy of myelodysplasia and acute promyelocytic leukemia.
    Blazsek I; Farabos C; Musset M; Goldschmidt E; Comisso M; Benavides M; Wang ZY; Labat ML; Mathé G; Misset JL
    Biomed Pharmacother; 1991; 45(4-5):169-77. PubMed ID: 1932600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [All-trans-retinoic acid in differentiation therapy of hemo-cytopathic proliferative diseases. II. Retinoids in clinical practice].
    Skotnicki AB; Sledziowski P; Sacha T; Jurczak W
    Przegl Lek; 1995; 52(4):145-6. PubMed ID: 7638362
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome.
    Greenberg BR; Durie BG; Barnett TC; Meyskens FL
    Cancer Treat Rep; 1985 Dec; 69(12):1369-74. PubMed ID: 3865701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.
    Kurzrock R; Estey E; Talpaz M
    J Clin Oncol; 1993 Aug; 11(8):1489-95. PubMed ID: 8336187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of differentiation-inducing agents in the myelodysplastic syndrome and acute non-lymphocytic leukemia.
    Hoffman SJ; Robinson WA
    Am J Hematol; 1988 Jun; 28(2):124-7. PubMed ID: 3293438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid.
    Clark RE; Smith SA; Jacobs A
    J Clin Pathol; 1987 Jun; 40(6):652-6. PubMed ID: 3475292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disappearance of cytogenetic abnormalities and clinical remission during therapy with 13-cis-retinoic acid in a patient with myelodysplastic syndrome: inhibition of growth of the patient's malignant monocytoid clone.
    Abrahm J; Besa EC; Hyzinski M; Finan J; Nowell P
    Blood; 1986 May; 67(5):1323-7. PubMed ID: 3457608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of 34 patients with myelodysplastic syndromes with 13-CIS retinoic acid.
    Bourantas KL; Tsiara S; Christou L
    Eur J Haematol; 1995 Oct; 55(4):235-9. PubMed ID: 7589340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome.
    Clark RE; Ismail SA; Jacobs A; Payne H; Smith SA
    Br J Haematol; 1987 May; 66(1):77-83. PubMed ID: 3297129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.